Skip to Content

'
Robert Z Orlowski, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Robert Z. Orlowski, MD, PhD, is Director of Myeloma, and Professor of Medicine

in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division

of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in

Houston, Texas. He is board-certified in internal medicine and medical oncology.

Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry

from Yale University and his medical degree from the Yale University School

of Medicine. He completed his internship and residency in Internal Medicine

at Barnes Hospital at the Washington University in St. Louis School of Medicine.

Dr. Orlowski has published numerous book chapters, articles, and abstracts

on cancer therapy, with a focus on the molecular pathogenesis of oncologic

disease processes and the mechanisms of action of chemotherapeutics.

 

Research Interests

His clinical research efforts focus on the translation of promising laboratory based

findings into novel clinical trials for patients with hematologic

malignancies. He has published in, and is a reviewer for, several journals,

including Blood, Cancer Research, Journal of Clinical Oncology, and the

New England Journal of Medicine. He has received several awards, including

The Leukemia & Lymphoma Society Scholar in Clinical Research and the

Jefferson-Pilot Fellowship in Academic Medicine.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Department of Lymphoma/Myeloma
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2042
Phone: 713-792-2860
Fax: 713-563-5067
Email: rorlowsk@mdanderson.org

Education & Training

Degree-Granting Education

1990 Yale University School of Medicine, New Haven, CT, PHD, Molecular Biophysics & Biochemistry
1983 Columbia College, Columbia University, New York, NY, BA, Chemistry

Postgraduate Training

7/1995-6/1998 Postdoctoral Fellowship, Adult Hematology, Johns Hopkins School of Medicine, Baltimore, MD, Dr. Chi V Dang
9/1994-6/1998 Postdoctoral Fellowship, Medical Oncology, Johns Hopkins Oncology Center, Baltimore, MD, Dr. Ross C Donehower
6/1991-6/1994 Internship and Residency, Internal Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, Drs. William E Clutter, Daniel M Goodenberger

Board Certifications

1997 American Board of Internal Medicine
1994 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2011
Associate Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2011
Lenvel Lee Rothrock Associate Professor, Pharmacology, Hematology/Oncology, The University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 11/2006-8/2007
Associate Professor, Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 6/2005-11/2006
Associate Professor, Medicine, Hematology/Oncology, The University of North Carolina and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 4/2005-11/2006
Assistant Professor, Medicine, Hematology/Oncology, The University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 7/1998-3/2005

Administrative Appointments/Responsibilities

Director, Section of Myeloma, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-present
Member, Lineberger Comprehensive Cancer Center, The University of North Carolina At Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007
Member, Molecular Therapeutics Program, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007
Member, Clinical Research Program, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 8/1998-8/2007

Other Appointments/Responsibilities

Chair, SWOG Search Committee for Lymphoma, Houston, TX, 1/2014-present
Member, AACR Clinical and Translational Cancer Research Grants Scientific Review Committee, Houston, TX, 1/2014-4/2015
Member, SWOG - Social Media Working Group, Houston, TX, 10/2013-present
Presenter, SWOG Fall Meeting 2013 Plenary Session, Best of SWOG Update: Myeloma, Chicago, IL, 10/2013
Member, NCI Cancer Drug Development Grant Review Committee, Bethesda, MD, 7/2013-present
Leader, SWOG Search Committee for Leukemia, Houston, TX, 10/2012-present
Chairman, Millennium Independent Data Monitoring Committee (IDMC) for C16010 Study, Houston, TX, 10/2012-present
Member, Celgene Sponsored - Pomalidomide Independent Adjudication Committee, Paris, France, 3/2012-present
Member, American Cancer Society - Cancer Drug Discovery Committee, Atlanta, GA, 1/2012-12/2015
Chair, SWOG Group/Barlogie Multiple Myeloma Committee, Houston, TX, 2011-present
Member, National Cancer Institute Myeloma Steering Committee (MYSC), Houston, TX, 2010-present
Member, Editorial Board, Journal of Clinical Oncology, Houston, TX, 2009-present
Member, Editorial Board, Expert Review of Hematology, Houston, TX, 2008-present
Member, American Society of Hematology Scientific Committee on Lymphoid Neoplasia, Houston, TX, 2006-2011
Member, Cancer and Leukemia Group B Leukemia Core Committee, Chapel Hill, NC, 1/2005-1/2008
Member, American Society for Biochemistry and Molecular Biology/ FASEB Member, Houston, TX, 2002-present

Institutional Committee Activities

Member, Promotion and Tenure Committee, 1/2013-8/2015
Committee Member, Institutional Review Grant (IRG) Committee, 8/2008-7/2011
Committee Member, The University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Protocol Review Committee, 1/2005-12/2007

Honors and Awards

2006 LLS Man of the Year, Leukemia and Lymphoma Society
2005 LLS Scholar In Clinical Research, Leukemia and Lymphoma Society
2004 Jefferson-Pilot Fellowship, Academic Medicine
2004 Triangle Business Journal Health Care Innovator, Research Award
2003 Young Investigator Award, Clinical Hematology Research
2000 Lymphoma Fellowship Award, Lymphoma Research Foundation of America, Lymphoma Research Foundation of America
1998 Merit Award, American Society of Clinical Oncology, American Society of Clinical Oncology
1983 B.A. in Chemistry form Columbia University Magna Cum Laude, Columbia University
1982 Macy Research Scholarship, Macy
1981 United Hospital Fund Volunteer Service Award, United Hospital Fund
1980-1983 Columbia College Dean's List, Columbia College
1978 Westinghouse Talent Search Honorable Mention, Westinghouse

Selected Publications

Peer-Reviewed Original Research Articles

1. Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib-resistance in multiple myeloma through a novel link between autophagy and apoptosis. Blood 124(17):2687-97, 10/2014. e-Pub 9/2014. PMCID: PMC4208284.
2. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Spicka I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma. Am J Hematol. e-Pub 10/2014. PMID: 25294016.
3. Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3(5):1275-83, 10/2014. e-Pub 6/2014. PMID: 24913924.
4. Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastritis E, Dimopoulos MA, Shah J. Therapy-Related Myelodysplastic Syndrome/Acute Leukemia After Multiple Myeloma in the Era of Novel Agents. Leuk Lymphoma. e-Pub 10/2014. PMID: 25284489.
5. Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal Analysis of Patient-Reported Symptoms Post-AuSCT and their Relationship to Inflammation in Patients with Multiple Myeloma. Leuk Lymphoma. e-Pub 9/24/2014. PMID: 25248883.
6. Dimopoulos MA, Orlowsky RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. e-Pub 9/2014. PMID: 25261096.
7. Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 Induces Cargo-Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik. Mol Cell Biol 34(18):3435-49, 9/2014. e-Pub 7/2014. PMCID: PMC4135623.
8. Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. Leuk Lymphoma. e-Pub 8/18/2014. PMID: 24844357.
9. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49(8):1036-41, 8/2014. e-Pub 6/2/2014. PMID: 24887378.
10. Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, Shah N. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ. e-Pub 8/2014. PMID: 25168239.
11. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 7/2014. PMID: 25107338.
12. Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y. Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer. e-Pub 7/2014. PMID: 25042852.
13. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111(3):628-36, 7/2014. e-Pub 6/2014. PMID: 24921909.
14. Tang G, Wang SA, Lu V, Lee HC, Qazilbash MH, Wang XI, Yin CC, Orlowski R, Wang Y, Patel A, Medeiros LJ, Lu G. Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leuk Res. e-Pub 6/2014. PMID: 24939217.
15. Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20(12):3174-86, 6/2014. e-Pub 4/2014. PMID: 24727327.
16. Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, Mendy D, Schafer P, Lopez-Girona A, Lentzsch S, Schey SA, Calle Y, Chelliah R, Orlowski RZ, Madan A, Avet-Loiseau H, Chopra R. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD® therapy. Leukemia 28(5):1129-31, 5/2014. e-Pub 10/2013. PMCID: PMC4017253.
17. San Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Goh YT, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ. Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newly diagnosed multiple myeloma. Blood. e-Pub 5/2014. PMID: 24833354.
18. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123(14):2204-8, 4/2014. e-Pub 1/2014. PMCID: PMC3975258.
19. Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant 49(3):465-6, 3/2014. e-Pub 1/2014. PMID: 24419515.
20. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. Clin Cancer Res 20(5):1366-74, 3/2014. e-Pub 1/2014. PMCID: PMC3947467.
21. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28(3):525-42, 3/2014. e-Pub 11/2013. PMID: 24253022.
22. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
23. Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7(1):127-41, 2/2014. e-Pub 12/2013. PMID: 24350987.
24. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H, International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2):269-77, 2/2014. e-Pub 8/2013. PMID: 23974982.
25. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. J Clin Oncol 32(6):587-600, 2/2014. e-Pub 1/2014. PMCID: PMC3918540.
26. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J, Orlowski RZ, Barlogie B. Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78-85, 1/2/2014. e-Pub 10/21/2013. PMCID: PMC3879908.
27. Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5):632-9, 1/30/2014. e-Pub 12/11/2013. PMID: 24335104.
28. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos M. The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma. Leuk Lymphoma 55(1):11-8, 1/2014. e-Pub 6/2013. PMID: 23614765.
29. Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells. PLoS One 9(3):e89064, 2014. e-Pub 3/2014. PMCID: PMC3942309.
30. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol 7(1):41, 2014. e-Pub 5/2014. PMCID: PMC4038108.
31. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 9/2014. PMCID: PMC4151993.
32. Anchoori RK, Karanam B, Peng S, Wang JW, Jiang R, Tanno T, Orlowski RZ, Matsui W, Zhao M, Rudek MA, Hung CF, Chen X, Walters KJ, Roden RB. A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer. Cancer Cell 24(6):791-805, 12/9/2013. PMCID: PMC3881268.
33. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
34. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12):2351-6, 12/2013. e-Pub 5/14/2013. PMCID: PMC3865533.
35. Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplant 48(12):1537-42, 11/2013. e-Pub 7/15/2013. PMCID: PMC3855173.
36. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122(18):3122-8, 10/31/2013. e-Pub 9/6/2013. PMCID: PMC3814729.
37. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/ Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 10/2013. e-Pub 7/17/2013. PMID: 23872222.
38. Orlowski RZ. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials. Semin Oncol 40(5):634-51, 10/2013. PMCID: PMC3819933.
39. Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, Bashir T, Vreys V, Orlowski RZ. The Novel Anti-cancer Agent JNJ-26854165 Induces Cell Death Through Inhibition of Cholesterol Transport and Degradation of ABCA1. J Pharmacol Exp Ther 346(3):381-92, 9/2013. e-Pub 7/2/2013. PMID: 23820125.
40. Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. e-Pub 8/2013. PMID: 23988451.
41. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 8/2013. e-Pub 5/2013. PMID: 23733001.
42. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 161(3):357-66, 5/2013. e-Pub 2/2013. PMID: 23432640.
43. Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ. Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms. Arch Pathol Lab Med 137(5):625-31, 5/2013. PMID: 23627452.
44. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib Dose-escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma. Clin Cancer Res 19(8):2248-56, 4/2013. e-Pub 2/2013. PMID: 23447001.
45. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27(4):780-91, 4/2013. e-Pub 11/2012. PMID: 23288300.
46. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12(6):459-62, 12/2012. e-Pub 9/2012. PMID: 23009979.
47. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 72(24):6393-402, 12/2012. e-Pub 10/2012. PMCID: PMC3525770.
48. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817-25, 10/2012. e-Pub 7/2012. PMID: 22833546.
49. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk 12(5):310-8, 10/2012. PMID: 23040437.
50. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA. Mol Cancer Ther 11(10):2243-53, 10/2012. e-Pub 8/2012. PMCID: PMC3469746.
51. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 10/2012. e-Pub 8/2012. PMCID: PMC3476538.
52. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
53. Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors up-regulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 72(16):4225-37, 8/2012. e-Pub 6/2012. PMCID: PMC3421040.
54. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: ten years later. Blood 120(5):947-59, 8/2012. e-Pub 5/2012. PMID: 22645181.
55. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Orlowski RZ, and Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br. J. Haematol. 158. e-Pub 7/2012. PMID: 22845873.
56. Kuhn DJ, Orlowski RZ. The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49(3):258-62, 7/2012. PMID: 22726549.
57. Zhang X, Jing Y, Qin Y, Hunsucker S, Meng H, Sui J, Jiang Y, Gao L, An G, Yang N, Orlowski RZ, Yang L. The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol 44(7):1166-73, 7/2012. e-Pub 4/2012. PMCID: PMC3358443.
58. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. e-Pub 10/2011. PMID: 22015451.
59. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood 119(24):5661-70, 6/2012. e-Pub 5/2012. PMID: 22555973.
60. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 5/2012. e-Pub 9/2011. PMID: 21887685.
61. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 119(16):3668-83, 4/2012. e-Pub 1/2012. PMCID: PMC3335376.
62. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/2012. PMID: 22231283.
63. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥ 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/2011. PMID: 21780997.
64. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119. e-Pub 1/2012. PMID: 22271445.
65. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26(1):149-157, 1/2012. e-Pub 7/2011. PMID: 21799510.
66. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, and Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22. e-Pub 2012. PMID: 22975377.
67. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26. e-Pub 12/2011. PMID: 22193964.
68. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon (CRBN) expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118(18):4771-9, 11/2011. e-Pub 8/2011. PMCID: PMC3208291.
69. Orlowski RZ. The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma. Oncology (Williston Park) 25(12 Suppl 2), 11/2011. PMID: 25188482.
70. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 10/2011. e-Pub 8/2011. PMCID: PMC3204731.
71. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/2011. e-Pub 3/2011. PMID: 21437886.
72. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311-21, 8/2011. e-Pub 6/2011. PMCID: PMC3156932.
73. Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 117(16):3758-62, 8/2011. e-Pub 2/2011. PMID: 21328327.
74. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase (ALP) variation during carfilzomib treatment is associated to best response in multiple myeloma patients. Eur J Haematol 86(6):484-7, 6/2011. e-Pub 4/2011. PMID: 21477075.
75. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group. International Myeloma Working Group (IMWG) consensus approach to the treatment of myeloma patients who are candidates for autologous stem-cell transplantation. Blood 117(23):6063-73, 6/2011. e-Pub 3/2011. PMID: 21447828.
76. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, International Myeloma Workshop Consensus Panel 1. Consensus recommendations for uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 152(18):579-592, 5/2011. e-Pub 2/2011. PMID: 21292775.
77. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(13):11009-20, 4/2011. e-Pub 12/2010. PMCID: PMC3064156.
78. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signaling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-592, 3/2011. e-Pub 1/2011. PMID: 21241278.
79. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating cyclin D2 expression in multiple myeloma. Oncogene 30(11):1329-40, 3/2011. e-Pub 11/2010. PMID: 21057542.
80. Kuhn DJ, Orlowski RZ, Bjorklund CC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets 11(3):285-95, 3/2011. PMID: 21247387.
81. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Lantz KC, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44-9, 2/2011. PMID: 21454189.
82. Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther 10(1):148-158, 1/2011. e-Pub 11/2010. PMID: 21062912.
83. Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer 10(6):465-470, 12/2010. PMID: 21147690.
84. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, Orlowski RZ. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89(11):1133-1140, 11/2010. e-Pub 6/2010. PMCID: PMC2940014.
85. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-2452, 10/2010. e-Pub 8/2010. PMCID: PMC2966770.
86. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Droger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121-1127, 2010. PMID: 20410922.
87. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085-7091, 11/2009. e-Pub 11/2009. PMID: 19903785.
88. Gloghini A, Buglio D, Khaskhely NM, Georgakis G, Orlowski RZ, Neelapu SS, Carbone A, Younes A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147(4):515-525, 11/2009. e-Pub 9/2009. PMID: 19775297.
89. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23(11):1964-1979, 11/2009. e-Pub 9/2009. PMID: 19741722.
90. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10):1716-1730, 10/2009. e-Pub 6/2009. PMID: 19494840.
91. Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you? Blood 113(23):5695-5696, 6/2009. PMID: 19498025.
92. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, Orlowski RZ. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145(4):481-490, 5/2009. e-Pub 3/2008. PMID: 19344406.
93. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113(19):4667-4676, 5/2009. e-Pub 12/2008. PMID: 19050304.
94. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-159, 2/2009. e-Pub 3/2009. PMID: 19436606.
95. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensingeer W, Comenzo RL, Kuman S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, SanMiguel J, Ludwig H. Hajek R, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadora M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV and Durie BG, with the IMWG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 23:1904-1912, 2009. PMID: 19494840.
96. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA and Durie BM. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23:1545-1556, 2009. PMID: 19421229.
97. Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63(1):99-107, 12/2008. e-Pub 3/2008. PMID: 18327587.
98. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8(6):352-355, 12/2008. PMID: 19064400.
99. Jones RJ, Chen Q, Voorhees PM, Young KH, Bruey-Sedano N, Yang D, Orlowski RZ. Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. Clin Cancer Res 14(17):5416-5425, 9/2008. PMID: 18765533.
100. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112(7):1529-1537, 4/2008. PMID: 18300257.
101. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649-1657, 3/2008. PMID: 18347166.
102. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 111(9):4690-4699, 2008. e-Pub 2/2008. PMID: 18305219.
103. Voorhees PM, Chen Q, Kuhn DJ, Kuhn DJ, Small GW, Hunsucker, SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in pre-clinical models of multiple myeloma. Clin Cancer Res 13(21):6469-6478, 2007. PMID: 17975159.
104. Small GW, Shi YY, Higgins LS and Orlowski RZ. Mitogen-activated protein kinasse phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67:4459-4466, 2007. PMID: 17483361.
105. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Su CM, Demo SD, Bennett MK, Van Leeuwen FWB, Chanan-Khan AA, Orlowski RZ. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 110(9):3281-3290, 2007. e-Pub 6/2007. PMID: 17591945.
106. Ryan DP, O'Neil BH, Supko JG, Lima CM, Dees EC, Appleman LJ, Clark J, Fidias P, Orlowski RZ, Kashala O, Eder JP, Kusack JC, Jr. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107:2688-2697, 2006. e-Pub 10/2006.
107. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1):51-61, 2006. PMID: 16401713.
108. Dees EC, Orlowski RZ. Targeting the ubiquitin-proteasome pathway in breast cancer therapy. Future Oncol 2(1):121-135, 2006. PMID: 16556079.
109. Orlowski RZ. The proteasome inhibitor bortezomib. Nat Clin Pract Oncol 3:16-17, 2006. PMID: 16407873.
110. Ramaswamy B, Povoski S, Rhoades C, Allen J, Hauger M, Young D, Burak W, Farrar W, Yee L, Kendear K, Somasundaram S, Orlowski RZ, Shapiro CL. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 93(1):67-74, 2005. PMID: 16184461.
111. Orlowski RZ. The ubiquitin-proteasome pathway from bench to bedside. Hematology 2005:220-225, 2005. PMID: 16304384.
112. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42 MAPK. J Pharmacol Exp Ther 307(3):861-869, 12/2003. e-Pub 10/2003. PMID: 14557375.
113. Richardson PG, Barlogie B, Berenseon J, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanina R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Esseltine D-L, Kauffman M, Schenkein DP and Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 6/2003. e-Pub 10/2003. PMID: 12826635.
114. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 9(17):6316-6325, 2003. PMID: 14695130.
115. Somasundaram S, Edmund, NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62(13):3868-3875, 2002. PMID: 12097302.

Abstracts

1. Orlowski RZ, Shi YY, Small GW. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 88(1)(9):S31, 2004. PMID: 17483361.
2. Shah JJ, Orlowski RZ, Alexanian R, Wang M, Thomas S, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat U, and Weber D. The regimen of lenalidomide (len), thalidomide (thal), and dexamethasone (dex) is active against relapsed and/or refractory multiple myeloma (RRMM) and overcomes lenalidomide resistance. 2011 International Myeloma Workshop. Submitted.

Book Chapters

1. Lee HC, Orlowski RZ. Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma. In: Resistance to Proteasome Inhibitors in Cancer. Ed(s) Q Ping Dou, B Bonavida. Springer: New York, 81-98, 2014.

Grant & Contract Support

Title: Mechanisms of Immunomodulatory Drug Activity, Resistance, and Sensitization in Myeloma
Funding Source: Mayo
Role: Principal Investigator
Duration: 4/1/2013 - 3/31/2018
 
Title: Novel approaches targeting high risk deletion 17p Myeloma
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 12/1/2012 - 11/30/2013
 
Title: Validating Biomarkers Predictive of Lenalidomide
Funding Source: MMRF
Role: Principal Investigator
Duration: 7/1/2012 - 6/30/2014
 
Title: Onyx Pre-Clinical Trials
Funding Source: Onyx Pharmaceuticals
Role: Principal Investigator
Duration: 12/16/2011 - 12/16/2013
 
Title: SWOG
Funding Source: University of Michigan SWOG
Role: Principal Investigator
Duration: 4/1/2011 - 12/31/2014
 
Title: Modeling of Elotuzumab and Lenalidomide Drug Resistance in Multiple Myeloma, grant awarded but contract pending
Funding Source: Bristol Myers Squibb
Role: Principal Investigator
Duration: 4/1/2011 - 3/31/2013
 
Title: Quality of Life and Symptom burden of Myeloma Patients in the Novel Agent Era, grant awarded but contract pending
Funding Source: Millennium Pharmaceuticals, Inc
Role: Principal Investigator
Duration: 3/1/2011 - 3/1/2014
 
Title: Genomic studies of drug resistance and toxicity in the novel agent era, grant awarded but contract pending
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 3/1/2011 - 2/28/2013
 
Title: Novel Strategies Targeting Proteolysis Applied to Myeloma Induction Therapy, grant awarded but contract pending
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2013
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma, Project 3, Targeting the HDM-2 E3 Ligase in Multiple Myeloma, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/22/2010 - 9/21/2015
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma Administrative Core Facility, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Core Facility Director
Duration: 9/22/2010 - 9/21/2015
 
Title: M.D. Anderson Cancer Center SPORE in Multiple Myeloma Developmental Research Program, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/22/2010 - 9/21/2015
 
Title: MD Anderson Cancer Center SPORE in Multiple Myeloma, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/22/2010 - 8/31/2015
 
Title: A Genome Wide Admixture Scan of Multiple Myeloma in African-Americans, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Cozen
Duration: 8/1/2010 - 5/31/2015
 
Title: Mechanisms of Lenalidomide Resistance, grant awarded but contract pending
Funding Source: MMRF
Role: Principal Investigator
Duration: 6/1/2010 - 6/30/2013
 
Title: Molecular Profiling of Multiple Myeloma at M. D. Anderson, grant awarded but contract pending
Funding Source: Millennium Pharmaceuticals, Inc
Role: Principal Investigator
Duration: 3/1/2010 - 2/28/2015
 
Title: Mechanisms of Lenalidomide Resistance in Multiple Myeloma, grant awarded but contract pending
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 11/1/2009 - 11/30/2012
 
Title: Mechanisms of Symptoms of Multiple Myeloma and its Therapy, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2009 - 8/31/2013
 
Title: Carolina Center for Nanotechnology Excellence, Project 2: "Smart" Nanoparticles for Cancer Therapy and Imaging, grant awarded but contract pending
Funding Source: Carolina Center for Nantechnology
Role: Co-Investigator
Principal Investigator: DeSimone
Duration: 9/1/2005 - 8/31/2010
 
Title: Targeting the Ubiquitin-Proteasome and Heat Shock Pathways as Therapy for Hematologic Malignancies, grant awarded but contract pending
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 7/1/2005 - 6/30/2010
 
Title: The Immunoproteasome as a Target for Multiple Myeloma Therapy, grant awarded but contract pending
Funding Source: MMRF
Role: Principal Investigator
Duration: 7/1/2005 - 6/30/2006
 
Title: Dual Proteasome and MAPK Inhibition in Cancer Therapy, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2004 - 8/28/2011
 
Title: SPORE in Breast Cancer, Project 7: Inhibition of Chemotherapy-Induced NF-kB, grant awarded but contract pending
Funding Source: NCI
Role: Co-Investigator
Principal Investigator: Earp, ES
Duration: 8/1/2001 - 7/31/2006
 
Title: Spore in Breast Cancer, Project 8: A Novel Chemotherapy for Breast Cancer, grant awarded but contract pending
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Earp, ES
Duration: 8/1/2001 - 7/31/2006
 
Title: Modeling of Carfilzomib and ONX 0912 Drug Resistance in Multiple Myeloma :An Overview of a Proposed Collaboration Between Onyx Pharmaceuticals, Inc., and The University of Texas M. D. Anderson Cancer Center, grant awarded but contract pending
Funding Source: Onyx Pharmaceuticals
Role: Principal Investigator

Last updated: 11/5/2014